Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 Spike S1, (B.1.1.529/Omicron), His Tag, 100µg  

Recombinant SARS-CoV-2 Spike S1, (B.1.1.529/Omicron), His Tag, 100µg

Recombinant SARS-CoV-2 Spike S1 Protein, (B.1.1.529/Omicron), AA Val 16 - Arg 685, expressed from human 293 cells (HEK293), His Tag

Synonyms: Recombinant, protein, Spike, S1 protein, Spike glycoprotein Subunit1, S glycoprotein Subunit1, Spike protein S1

More details

S1N-C52Ha-100

Availability: within 7 days

494,00 €

Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant SARS-CoV-2 Spike S1, His Tag (B.1.1.529/Omicron) (S1N-C52Ha) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Arg 685 (Accession # QHD43416.1(A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H)). The spike mutations are identified on the SARS-CoV-2 Omicron variant (Pango lineage: B.1.1.529; GISAID clade: GR/484A; Nextstrain clade: 21K).
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 76.9 kDa. The protein migrates as 110-130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2"
Maeda, Toyoda, Kuwata et al
Int J Mol Sci (2024) 25 (2)
(2) "MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans"
Mayer, Weskamm, Fathi et al
NPJ Vaccines (2024) 9 (1), 20
(3) "Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine"
Muranishi, Kinoshita, Inoue et al
Vaccines (Basel) (2023) 12 (1)
Showing 1-3 of 2903 papers